• 1. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 2. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

Introduction to 6-Chloro-7H-purin-8(9H)-one (CAS No. 37527-48-3)

The compound 6-Chloro-7H-purin-8(9H)-one, also known by its CAS registry number 37527-48-3, is a synthetic purine derivative that has garnered significant attention in the field of biomedical research. This molecule belongs to a class of compounds that are closely related to naturally occurring purines, which are fundamental building blocks of nucleic acids. The presence of the chloro group at the 6-position introduces unique chemical properties and biological activity, making it a subject of interest for researchers exploring its potential applications in pharmacology and therapeutic development.

Recent studies have highlighted the importance of understanding the structural features of purine derivatives like 6-Chloro-7H-purin-8(9H)-one. The molecule's structure, characterized by a bicyclic framework with a keto group at position 8 and a hydroxyl group at position 7, contributes to its stability and reactivity in biological systems. This makes it a valuable tool for investigating nucleoside analogs and their interactions with enzymes and receptors involved in metabolism and signal transduction.

One of the most promising avenues of research involving 6-Chloro-7H-purin-8(9H)-one is its potential as an enzyme inhibitor. Purine derivatives have been extensively studied for their ability to inhibit key enzymes in pathways relevant to diseases such as cancer, inflammation, and viral infections. For instance, the compound's interaction with purine nucleoside phosphorylase (PNP) has been a focal point of recent investigations. Understanding these interactions at a molecular level can provide insights into designing more effective anticancer agents or antiviral drugs.

Another area of interest is the exploration of 6-Chloro-7H-purin-8(9H)-one in the context of nucleoside reverse transcriptase inhibitors (NRTIs). These inhibitors are a cornerstone of antiretroviral therapy, used to treat HIV/AIDS. The structural similarity between purine derivatives and natural nucleosides makes them ideal candidates for this purpose. Recent advancements in drug delivery systems and targeted therapies have further emphasized the need for compounds like 6-Chloro-7H-purin-8(9H)-one to be evaluated for their potential as next-generation NRTIs.

Furthermore, the compound's role in immunomodulatory agents has been explored. Purine derivatives are known to modulate immune responses by interacting with receptors on immune cells. The chloro substitution at position 6 appears to enhance the compound's ability to modulate T-cell activation and cytokine production, making it a potential candidate for immunotherapies. This aligns with the growing trend in precision medicine, where targeted modulation of immune responses is key to treating complex diseases.

Recent advancements in crystallography and molecular modeling have provided unprecedented insights into the binding modes of 6-Chloro-7H-purin-8(9H)-one with its target enzymes. These studies have revealed that the compound's keto group at position 8 plays a critical role in hydrogen bonding with key residues in the enzyme active site. This understanding is crucial for rational drug design, as it allows researchers to optimize the compound's structure for improved binding affinity and selectivity.

Moreover, the study of 6-Chloro-7H-purin-8(9H)-one has contributed to our understanding of purine metabolism. The enzyme purine nucleoside phosphorylase (PNP) is central to this pathway, catalyzing the conversion of purine nucleosides to their corresponding ribonucleotides. Inhibitors of PNP are being explored as potential therapies for diseases characterized by altered purine metabolism, such as gout and certain types of cancer.

Recent collaborative efforts between academic institutions and pharmaceutical companies have accelerated the discovery of novel purine-based drugs. These partnerships have facilitated access to advanced technologies, enabling researchers to systematically evaluate the potential of compounds like 6-Chloro-7H-purin-8(9H)-one in preclinical models. Such collaborative approaches are essential for translating laboratory findings into clinical applications.

Looking ahead, the future of 6-Chloro-7H-purin-8(9H)-one lies in its continued exploration as a drug candidate. Ongoing research is focused on optimizing its pharmacokinetic properties, such as bioavailability, half-life, and toxicity profile. These studies are critical for determining the compound's suitability as a therapeutic agent and for guiding further development.

In summary, 6-Chloro-7H-purin-8(9H)-one (CAS No. 37527-48-3) is a versatile compound with significant potential in the field of biomedical research. Its unique structural features and biological activity make it a valuable tool for investigating enzyme inhibition, nucleoside analogs, and immunomodulation. As research progresses, this compound is expected to contribute to the development of novel therapies for a wide range of diseases.

• 1688-98-8(2,6-dichloro-7,9-dihydro-7-methyl-8H-Purin-8-one)
• 49581-67-1
• 1226804-17-6(6-Chloro-7-methyl-7H-purin-8(9H)-one)
• 1226804-22-3(6-Chloro-7-isopropyl-7h-purin-8(9h)-one)
• 98138-76-2(8H-Purin-8-one, 6-chloro-3,7-dihydro-2-(methylthio)-)
• 7501-32-8(formamide, n-(4-amino-6-chloro-5-pyrimidinyl)-)
• 98027-86-2(2,6-dichloro-7H-purin-8-ol)
• 98136-62-0(2-amino-6-chloro-7,9-dihydro-8H-Purin-8-one)
• 885500-44-7(6-chloro-7-ethyl-7,9-dihydro-8H-Purin-8-one)
• 84602-79-9(6-Chloro-9-methyl-7H-purin-8(9H)-one)